ArticleFrontiers in chemistry2025
Membrane-targeting antibacterial isoniazid schiff base against
Article in Frontiers in chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Membrane-targeted schiff base derivatives overcome MRSA resistance through phosphatidylglycerol binding and ROS-mediated killing.Frontiers in chemistry · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Building upon previous research, this study focuses on the replication and evaluation of a series of hydrazone derivatives derived from isoniazid. Methods: The lead compound, identified as C5, was assessed for its antibacterial activity against Gram-positive bacteria, notably Staphylococcus aureus ATCC 29213. Its hemolytic potential, cytotoxicity (against VERO cells), and ability to induce resistance were evaluated. Mechanistic studies included assays for membrane depolarization (using DiSC35 fluorescence), membrane integrity (via SYTOX Green uptake), measurement of intracellular ATP levels, and detection of reactive oxygen species (ROS). Additional investigations examined its effect on LPS-induced NO/TNF-α release in macrophages and its activity against Results: Compound C5 exhibited potent antibacterial activity (MIC = 16 μg/mL against Discussion: These results demonstrate that C5 possesses a multifunctional mechanism of action, combining direct bactericidal activity through membrane targeting with anti-biofilm efficacy and immunomodulatory properties. This multifaceted profile highlights its strong potential as a promising candidate for combating resistant bacterial infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.